LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

Search

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

72.33 0.11

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

71.65

Max

73.28

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-100M

-229M

Pardavimai

46M

203M

Pelno marža

-112.808

Darbuotojai

1,402

EBITDA

4.7B

4.6B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+32.07% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.3B

12B

Ankstesnė atidarymo kaina

72.22

Ankstesnė uždarymo kaina

72.33

Naujienos nuotaikos

By Acuity

50%

50%

156 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-17 22:42; UTC

Uždarbis

Prudential PLC 2025 Adjusted Operating Profit Rises

2026-03-17 21:40; UTC

Uždarbis

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

2026-03-17 23:56; UTC

Rinkos pokalbiai

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

2026-03-17 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise After Recent Selloffs -- Market Talk

2026-03-17 23:42; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-17 23:42; UTC

Rinkos pokalbiai

RBA's Return to Policy Tightening Will Work -- Market Talk

2026-03-17 23:38; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

2026-03-17 23:24; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-03-17 23:24; UTC

Rinkos pokalbiai

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

2026-03-17 22:22; UTC

Rinkos pokalbiai

BHP Hands Reins to Growth-Focused Executive -- Market Talk

2026-03-17 22:20; UTC

Uždarbis

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

2026-03-17 22:20; UTC

Uždarbis

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

2026-03-17 22:07; UTC

Uždarbis

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

2026-03-17 22:05; UTC

Uždarbis

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

2026-03-17 22:04; UTC

Uždarbis

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

2026-03-17 22:03; UTC

Uždarbis

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

2026-03-17 22:01; UTC

Uždarbis

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

2026-03-17 22:01; UTC

Uždarbis

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

2026-03-17 22:01; UTC

Uždarbis

ZTO Express (Cayman) 4Q EPS 47c >ZTO

2026-03-17 21:26; UTC

Uždarbis

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

2026-03-17 21:09; UTC

Uždarbis

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

2026-03-17 21:08; UTC

Uždarbis

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

2026-03-17 21:08; UTC

Uždarbis

Couche-Tard 3Q Adj EPS 81c >ATD.T

2026-03-17 21:07; UTC

Uždarbis

Couche-Tard 3Q EPS 82c >ATD.T

2026-03-17 21:06; UTC

Uždarbis

Couche-Tard 3Q Rev $21.8B >ATD.T

2026-03-17 21:05; UTC

Uždarbis

Couche-Tard 3Q Adj EPS 81c >ATD.T

2026-03-17 21:05; UTC

Uždarbis

Couche-Tard 3Q Rev $21.8B >ATD.T

2026-03-17 21:05; UTC

Uždarbis

Couche-Tard 3Q EPS 82c >ATD.T

2026-03-17 21:05; UTC

Uždarbis

Couche-Tard 3Q Net $757.2M >ATD.T

2026-03-17 20:50; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Energy & Utilities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

32.07% į viršų

12 mėnesių prognozė

Vidutinis 95.54 USD  32.07%

Aukščiausias 110 USD

Žemiausias 72 USD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

14 ratings

11

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

156 / 351 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat